Use of mesoglycan in the acute phase of hemorrhoidal disease, the aCute HaemORrhoidal MEsoglycan Study (CHORMES): A double-blind, randomized controlled trial.
SurgeryJun 19, 2026 (epub)
Clinical ResearchGastroenterology
Gaetano Gallo, Antonella Salvatore, Giovanni Tomasicchio et al.
✦ AI-curated · Sources linked
In 30 seconds
The aCute HaemORrhoidal MEsoglycan Study was a double-blind, randomized controlled trial assessing mesoglycan's efficacy in adults with symptomatic grade II to III hemorrhoidal disease. The study found that mesoglycan significantly reduced the Hemorrhoidal Disease Symptom Score compared to placebo (-7.5 ± 5.9 vs -3.9 ± 5.4; P = .027).
Key findings
- Mesoglycan reduced the Hemorrhoidal Disease Symptom Score significantly more than placebo (-7.5 ± 5.9 vs -3.9 ± 5.4; P = .027).
- Significant reductions in itching (P = .0048), pain (P = .0246), and swelling/prolapse (P = .0418) were observed in the mesoglycan group.
- Bleeding improved significantly in the grade III subgroup (P = .03).
- Treatment adherence exceeded 97% in both arms.
Why it matters
This study highlights the potential of mesoglycan as an effective treatment option for managing acute hemorrhoidal disease symptoms, which can significantly impact patients' quality of life.